Abametapir and Netupitant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordNetupitant
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Abametapir is a lotion used to treat head lice. Even though it's applied to the scalp, some of it gets into your body and can slow down a liver enzyme called CYP3A4 for a couple of weeks. Netupitant (used to help prevent nausea from chemotherapy) is broken down by that same enzyme.
So if you use them close together, your body may clear netupitant more slowly, and its levels could build up and cause more side effects. The good news is this is easy to plan around. Please talk with your pharmacist or doctor about timing these two so they don't overlap.
Mechanism: Abametapir is a CYP3A4 inhibitor; netupitant is a CYP3A4 substrate. Inhibition reduces netupitant metabolism, increasing its systemic exposure (AUC/Cmax).
- Direction: increased netupitant exposure and potential toxicity.
- Onset: rapid; inhibition can persist for ~2 weeks after topical application.
- Evidence: theoretical, but severity rated major.
- Management: Avoid CYP3A4 substrates, including netupitant, within 2 weeks of abametapir application. If concomitant use is unavoidable, avoid abametapir instead. Consider closer monitoring for netupitant-related adverse effects if exposure occurs.
What happens
Increased exposure of CYP3A4 substrate
Interaction Deep Dive
Within a 2 week window following the application of abametapir, the concurrent use of CYP3A4 substrates should be avoided. Should that not be practical, abametapir itself should be avoided 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by abametapir
How to manage this interaction
What your care team may do:
- Separate these medications in time. The recommendation is to avoid CYP3A4 substrates like netupitant for about 2 weeks after applying abametapir.
- If you truly need netupitant during that window, your team may choose to avoid the abametapir treatment instead.
- If both must be used, your team may monitor you more closely for stronger netupitant side effects.
What you should do: Keep taking your medications as prescribed, and let your pharmacist or prescriber know you may need both so they can plan the timing safely.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abametapir and Netupitant together?
Abametapir can slow the breakdown of netupitant for up to two weeks, raising its levels; space them apart and let your pharmacist or doctor coordinate the timing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abametapir and Netupitant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How is the Abametapir and Netupitant interaction managed?
What your care team may do: Separate these medications in time. The recommendation is to avoid CYP3A4 substrates like netupitant for about 2 weeks after applying abametapir. If you truly need netupitant during that window, your team may choose to avoid the abametapir treatment instead. If both must be used, your team may monitor you more closely for stronger netupitant side effects. What you shoul… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abametapir or Netupitant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
Keep reading about Netupitant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist